SkyCell and Japan Airlines partner to support the growing Japanese pharmaceutical shipment market
SkyCell, the manufacturer of innovative hybrid pharmaceutical containers, has partnered with Japan Airlines Cargo (JAL Cargo), to meet the country’s growing needs for vaccine and pharmaceutical transportation in a safe, secure, and sustainable way.
SkyCell is committed to working with JAL Cargo to offer a tailor-made solution that meets the airline’s growing business needs across vaccine and pharmaceutical shipments. This partnership will also see SkyCell further strengthen its presence in Japan and continue to support the temperature sensitive pharmaceutical market with its high-quality hybrid containers that have been industry accredited to have near zero spoilage rates.
“I see this partnership with JAL as a firm commitment from SkyCell to support the Japanese pharmaceutical market. We play a key role together in delivering life-saving medicine in the most safe, secure and sustainable way to the patients in need. A great journey starts with small steps, and we look forward to working together with a common mission focused on ensuring patients get the life-saving medicines they need in a sustainable and secure way.”
SkyCell’s GDP compliant hybrid containers – which maintain internal temperature stability across the pharmaceutical industry recognised temperature ranges, without the need for external intervention – are able to cover customers’ various needs. By using lightweight, environmentally friendly material, the technology enables efficiency and reusability. The Swiss engineered hybrid features include shock-absorbent feet to mitigate any breakage during transport and has a double-door system to protect the packing against humidity.
“On the signing of a Master Lease Agreement, JAL and SkyCell will work in close cooperation and coordination to provide our customers with peace of mind when using SkyCell containers, which have a temperature excursion rate of less than 0.1% and are capable of maintaining the required temperature range at the highest levels, and do not need electric power.”
The partnership between SkyCell and JAL is a first step into a joint vision to determinedly, faithfully, and creatively increase the shipment quality of highly valuable and sensitive products.
News & Stories
Supporting Vaccine Distribution Across the Globe
In an increasingly complex world, the collaboration between pharma companies and supply chain partners has never been more important, particularly...
SkyCell and Validaide Partner to Revolutionize Pharma Supply Chain
We are excited to announce our partnership with Validaide, a leading platform in lane risk assessment, to improve decision-making and...
SkyCell closes US$116 million Series D
In a significant development, SkyCell has secured a $57 million funding round in partnership with Catalyst, M&G Investments' $6 billion...